The successful commercial dispatch represents the beginning of full-scale execution under the long-term manufacturing mandate and reflects the company's progress in strengthening its position in global pharmaceutical manufacturing. The development follows the completion of validation processes, manufacturing preparedness, and supply chain planning required for commercial production.
Commenting on the achievement, Managing Director Sanjay Suri said the milestone reflects Morepen Laboratories' strategic transition toward long-duration global manufacturing partnerships. He stated that the company's teams worked closely with the customer throughout the validation process, manufacturing readiness, and supply chain planning. With commercial supplies now underway, the company is focused on scaling production, expanding manufacturing capacity, and strengthening its CDMO platform through additional customer engagements and product opportunities.
Following the successful dispatch of the first commercial batch, Morepen Laboratories expects to significantly increase supplies during the second quarter of the financial year 2026-27. The company anticipates additional commercial dispatches worth approximately Rs. 225 crore during the quarter, subject to customer schedules and the fulfillment of regulatory and commercial requirements.
To support the growing demand for large-scale CDMO projects, the company is continuing to strengthen its manufacturing infrastructure. Morepen Laboratories expects its total reactor capacity to reach approximately 600 kilolitres by the end of the second quarter, with further expansion planned to approximately 800 kilolitres and subsequently 1,000 kilolitres in future phases.
The commencement of commercial supplies under the Rs. 825 crore mandate reinforces the company's long-term strategy of building a scalable CDMO platform, strengthening customer partnerships, and expanding its participation in long-duration global manufacturing opportunities.
Morepen Laboratories Limited operates across multiple segments of the pharmaceutical and healthcare industry, including active pharmaceutical ingredients, finished formulations, diagnostics, and consumer healthcare. The company continues to enhance its manufacturing capabilities, research infrastructure, and regulatory expertise to support sustained growth in domestic and international markets.
The company also noted that certain statements regarding future business prospects, expansion plans, expectations, and financial performance are forward-looking in nature. These statements are based on current assumptions and remain subject to various risks and uncertainties that could result in actual outcomes differing materially from expectations. Morepen Laboratories clarified that it does not undertake any obligation to revise or update such forward-looking statements except where required under applicable law.
The first commercial execution under the Rs. 825 crore CDMO mandate marks a significant step in Morepen Laboratories' manufacturing expansion strategy, highlighting its readiness to execute large-scale global pharmaceutical partnerships while strengthening production capacity and long-term business growth.
About The Author
Comment List